SEC Comment Letter 0000000000-24-002871 to Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc.
Date: March 15, 2024 · CIK: 0001937993 · Accession: 0000000000-24-002871
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277835
Letter
United States securities and exchange commission logo March 15, 2024 Quang Pham President, Chief Executive Officer and Director Cadrenal Therapeutics, Inc. 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 Re:Cadrenal Therapeutics, Inc. Registration Statement on Form S-3 Filed March 12, 2024 File No. 333-277835 Dear Quang Pham: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Leslie Marlow, Esq.
Show Raw Text
United States securities and exchange commission logo
March 15, 2024
Quang Pham
President, Chief Executive Officer and Director
Cadrenal Therapeutics, Inc.
822 A1A North, Suite 306
Ponte Vedra, Florida 32082
Re:Cadrenal Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 12, 2024
File No. 333-277835
Dear Quang Pham:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Leslie Marlow, Esq.